Prostate cancer is the second most common cancer in men, affecting millions worldwide. Over the past few years, significant advancements have been made in understanding the disease’s biology, leading to improved diagnostic methods and more effective therapies. This article provides an overview of the current state of prostate cancer therapy, touching on both traditional and emerging treatments and the challenges faced in providing personalised care for patients.
Conventional Treatments
Emerging Treatments
Challenges in Personalised Care
Despite the advancements in prostate cancer therapy, challenges remain in providing personalised care for patients. The heterogeneity of the disease, variable treatment responses, and resistance mechanisms complicate the selection of optimal therapies. Moreover, access to cutting-edge treatments can be limited due to high costs and availability in certain regions.
[wpseo_breadcrumbs]
By
| 7 minutes of readingLearn about the transformative role of AI in prostate cancer diagnosis, improving detection and consistency for better outcomes. Image for illustration only. People depicted are models.
Revolution in Men’s Health: AI Breakthrough in Prostate Cancer Diagnosis Read Article »
By
| 3 minutes of readingExplore the FLEX-MRT trial for FLEX-MRT prostate cancer, evaluating a flexible dosing schedule for improved survival outcomes.
FLEX-MRT: Individualised Lu-177 PSMA-617 Scheduling for Advanced Prostate Cancer Read Article »
By
| 8 minutes of readingDiscover how gozetotide changes prostate cancer diagnosis with improved accuracy and a focus on PSMA imaging technologies.
By
| 7 minutes of readingDiscover how radioisotopes in medicine enhance diagnostics and treatments. Learn about their significance and uses today.
Radioisotopes in Science: Uses, Safety and Applications Read Article »
By
| 4 minutes of readingModern prostate cancer treatment includes early detection, targeted therapies, and personalised care for improved patient outcomes and recovery.
Modern Approaches to Prostate Cancer Treatment: From Early Detection to Recovery Read Article »
By
| 14 minutes of readingRadiotheranostics and radiotherapeutics cancer treatments provide personalised care by combining diagnosis and targeted therapy.
Radiotheranostics and Radiotherapeutics in Cancer Diagnosis and Treatment Read Article »
By
| 11 minutes of readingAlpha particle emitting radionuclides are highly effective in delivering targeted radiation therapy for various cancers.
Selected Alpha Particle Emitting Radionuclides for Therapeutic Nuclear Medicine Read Article »
By
| 13 minutes of readingRadioactive isotopes emit targeted radiation that effectively destroys cancer cells while minimising harm to healthy tissues.
Biological Principles Underpinning Targeted Radionuclide Therapy for Cancer Read Article »
By
| 11 minutes of readingThorium-227 Pelgifatamab utilises PSMA targeting and alpha emissions to destroy cancer cells while sparing healthy tissue effectively.
By
| 12 minutes of readingTerbium-161 PSMA-I&T combines precise PSMA targeting with beta and Auger emissions, revolutionising prostate cancer treatment efficacy.
Terbium-161 PSMA-I&T: A New Frontier in Targeted Radioligand Therapy Read Article »
By
| 10 minutes of readingStrontium-89 Chloride Therapy delivers targeted beta emissions to osteoblastic lesions, often reducing malignant bone pain substantially.
By
| 11 minutes of readingTin-117m DTPA offers innovative treatment options for bone metastases, combining therapeutic efficacy with minimal collateral tissue damage.
The Rise, Fall, and Revival of Tin-117m DTPA Read Article »
By
| 11 minutes of readingSamarium-153 Lexidronam remains a reliable radiopharmaceutical delivering targeted beta radiation, alleviating painful metastases in suitable patients.
By
| 10 minutes of readingRhenium-186 Etidronate, a radiopharmaceutical, delivers beta radiation to metastatic bone lesions, effectively reducing cancer-related pain.
Rhenium-186 Etidronate: Development, Clinical Role, and Worldwide Implications Read Article »
By
| 10 minutes of readingRadium-223 Dichloride is a groundbreaking alpha-emitting radiopharmaceutical offering significant survival benefits for metastatic prostate cancer patients.
Radium-223 Dichloride: Transforming the Landscape of Bone Metastatic Cancer Treatment Read Article »
By
| 15 minutes of readingLead-212 ADVC001 offers innovative alpha-emitting therapy, targeting PSMA-positive mCRPC with precise and potent tumour eradication.
By
| 5 minutes of readingLutetium-177 XT033 combines PSMA targeting and Evans blue technology to improve metabolic stability and therapeutic effectiveness.
By
| 7 minutes of readingLutetium-177 Rosopatamab is a radiopharmaceutical therapy combining targeted monoclonal antibodies with beta-emitting radioactive particles.
By
| 4 minutes of readingLutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
By
| 5 minutes of readingLutetium-177 PSMA-ALB-56 is an innovative treatment optimising prostate cancer therapy through targeted radiopharmaceutical advancements.
Lutetium-177 PSMA-ALB-56: A Promising Radiopharmaceutical for Prostate Cancer Therapy Read Article »
By
| 5 minutes of readingLutetium-177 PNT2002 offers targeted radiotherapy for prostate cancer, combining precise tumour targeting with therapeutic and diagnostic capabilities.
Lutetium-177 PNT2002: A Promising PSMA-Targeted Radiopharmaceutical Read Article »
By
| 10 minutes of readingLutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
By
| 5 minutes of readingLutetium-177 iPSMA revolutionises prostate cancer treatment, delivering targeted beta radiation to metastatic cells with precision and minimal side effects.
Lutetium-177 iPSMA: A Game-Changer in Prostate Cancer Therapy Read Article »
By
| 5 minutes of readingLutetium-177 EDTMP provides a cost-effective, accessible, and efficacious alternative for bone pain palliation in metastatic cancer patients.
Lutetium-177 EDTMP: A Cost-Effective Alternative for Bone Pain Palliation in Cancer Read Article »
By
| 11 minutes of readingLutetium-177 EB-PSMA-617 represents an innovative radioligand therapy optimising tumour retention and therapeutic outcomes in metastatic prostate cancer.
By
| 10 minutes of readingLutetium-177 DOTAZOL offers a dual-function approach, combining targeted radiotherapy and bone modulation, enhancing treatment for prostate cancer-related bone metastases.
By
| 10 minutes of readingLutetium-177 DOTA-EB-TATE enhances neuroendocrine tumour therapy by improving tumour uptake, retention, and pharmacokinetics through albumin-binding Evans blue moieties.
Neuroendocrine Tumour Therapy: The Rise of Lutetium-177 DOTA-EB-TATE Read Article »
By
| 5 minutes of readingLutetium-177 CTT1403, an innovative PSMA-targeted therapy with irreversible phosphoramidate-based binding, shows remarkable efficacy in treating metastatic prostate cancer, enhancing tumour uptake, internalisation, and therapeutic precision.
Lutetium-177 CTT1403: A Therapeutic Breakthrough in Prostate Cancer Treatment Read Article »
By
| 5 minutes of readingIodine-131 RPS-001, a radiolabelled small molecule targeting PSMA, shows promise in prostate cancer therapy through precision-directed beta radiation delivery.
Iodine-131 RPS-001: A Promising Radiolabelled Molecule in Prostate Cancer Therapy Read Article »
By
| 8 minutes of readingAdvancements in Proton Beam Therapy have led to better cancer treatments with fewer side effects.
Advancements in Proton Beam Therapy: A New Frontier in Cancer Treatment Read Article »
By
| 8 minutes of readingRadiotheranostics in prostate cancer enables precise diagnosis and targeted treatment, improving patient outcomes significantly.
Radiotheranostics in Prostate Cancer: A New Frontier in Precision Treatment Read Article »
